Why does a higher repseonse rate to chemotherapy correlate poorly with improved survival?
- 16 Downloads
- Doroshow JH, Multhauf P, Leong L, Margolin K, Litchfield T, Akman S, Carr B, Bertrand M, Goldberg D, Blayney D, Odujinrin O, DeLap R, Shuster J, Newman E (1990) Prospective randomized comparison of fluorouracil versus fluorouracil and high-dose continuous infusion leucovorin calcium for the treatment of advanced measurable colorectal cancer in patients previously unexposed to chemotherapy. J Clin Oncol 8:491–501PubMedGoogle Scholar
- Ganz PA, Figlin RA, Haskell CM, La Soto N, Siau J (1988) Supportive care versus supportive care and combination chemotherapy in metastatic non-small cell lung cancer. Does chemotherapy make a difference? Cancer 63:1271–1278Google Scholar
- Kemeny N, Israel K, Niedzwiecki D, Chapman D, Botet J, Minsky B, Vinciguerra V, Rosenbluth R, Bosselli B, Cochran C, Sheehan K (1990) Randomized study of continuous infusion fluorouracil versus fluorouracil plus cisplatin in patients with metastatic colorectal cancer. J Clin Oncol 8:313–318PubMedGoogle Scholar
- Rapp E, Pater JL, Willan A, Cormier Y, Murray N, Evans WK, Hodson DI, Clark DA, Feld R, Arnold AM, Ayoub JI, Wilson KS, Latreille J, Wierzbicki RF, Hill DP (1988) Chemotherapy can prolong survival in patients with advanced non-small-cell lung cancer-Report of a Canadian multicenter radomized trial. J Clin Oncol 6:633–641PubMedGoogle Scholar
- Woods RL, Williams CJ, Levi J, Page J, Bell D, Byrne M, Kerestes ZL (1989) A randomized trial of cisplatin and vindesine versus supportive care only in advanced non-small cell lung cancer. Brit J Cancer 61:608–611Google Scholar
© Springer-Verlag 1993